Sofosbuvir/Velpatasvir/Voxilaprevir

DRUG3 trials

Sponsors

University of Maryland, Baltimore, University of California, San Francisco, Peking University People's Hospital

Conditions

Chronic Hepatitis CCirrhosisHepatitis CTransplantation Disease Transmission

Phase 2

Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience

CompletedNCT02745535

University of Maryland, BaltimoreChronic Hepatitis C

Start: 2016-05-31End: 2018-10-24Updated: 2022-03-10

Phase 4

Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant

CompletedNCT03619837

University of California, San FranciscoHepatitis C, Transplantation Disease Transmission

Start: 2018-07-15End: 2020-08-13Updated: 2021-03-03

Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis

Peking University People's HospitalCirrhosis, Hepatitis C

Start: 2022-09-01End: 2023-12-31Target: 100Updated: 2022-07-21

Related Papers

Sofosbuvir/Velpatasvir/Voxilaprevir Versus Sofosbuvir/Velpatasvir Plus Ribavirin in Patients With Hepatitis C Virus Genotype 3b and Compensated Cirrhosis: A Multicentre Randomized Controlled Trial.

2025-11-01